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Abstract
There has been growing interest for small molecule CD4 mimetic compounds due to their capability to
inhibit the HIV-1 entry and possibility to eradicate infected cells in livings. Certain experiments also prove
that a lead compound, BNM-III-170 (+)-1
(+)-1, developed in the laboratory has direct antiviral effect and could
sensitize HIV-infected cells toward Antibody-Dependent Cellular Cytotoxicity (ADCC). An efficient and
scalable process synthesis for the HIV-1 entry inhibitor BNM-III-170 bis-TFA salt (+)-1 is described herein
for further investigations. The synthesis employs a state-of-the-art dynamic-kinetic resolution (DKR) both
to generate the stereogenicity and significantly reduce the number of chromatographic separations
throughout the synthesis. By taking advantage of some modifications from the first-generation synthesis,
along with the low solubility of late stage intermediate, the scale-up synthesis has been greatly improved
from a few hundred milligrams in 6.2% yield over a 15- step sequence. Now to proceed on a 20-gram or
larger scale in overall 16 steps and in 9.64% yield, requiring only one chromatographic separation.
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There has been growing interest for small molecule CD4 mimetic compounds due to their
capability to inhibit the HIV-1 entry and possibility to eradicate infected cells in livings.
Certain experiments also prove that a lead compound, BNM-III-170 (+)-1, developed in
the laboratory has direct antiviral effect and could sensitize HIV-infected cells toward
Antibody-Dependent Cellular Cytotoxicity (ADCC). An efficient and scalable process
synthesis for the HIV-1 entry inhibitor BNM-III-170 bis-TFA salt (+)-1 is described herein
for further investigations. The synthesis employs a state-of-the-art dynamic-kinetic
resolution (DKR) both to generate the stereogenicity and significantly reduce the number
of chromatographic separations throughout the synthesis. By taking advantage of some
modifications from the first-generation synthesis, along with the low solubility of late stage
intermediate, the scale-up synthesis has been greatly improved from a few hundred
milligrams in 6.2% yield over a 15- step sequence. Now to proceed on a 20-gram or larger
scale in overall 16 steps and in 9.64% yield, requiring only one chromatographic separation.
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Introduction
Reprinted with permission from (J.
Lippincott, B. Melillo, and A. B.
Enantioselective Synthesis of the
Trifluoroacetate Salt. Org. Process
American Chemical Society.

Chen, J. Park, S. M. Kirk, H-C. Chen, X. Li, D. J.
Smith, III. Development of an Effective Scalable
HIV-1 Entry Inhibitor BNM-III-170 as the BisRes. Dev. 2019, 23, 2464-2469). Copyright (2020)

The Human immunodeficiency virus (HIV) is responsible for the acquired
immunodeficiency syndrome (AIDS), which has been a global pandemic. Currently, 37.9
million people are living with AIDS, with approximately 1.8 million people new infections
reported each year, and with around 32 million people having died from AIDS-related
illnesses since the start of the epidemic.1 Although combination therapy, like antiretroviral
or ART has proven to be successful to improve the quality of the lives of the infected
patients, a cure for AIDS or a vaccine against HIV-1 remains to be found.
The gp120-gp41 glycoprotein trimer is the only virus-specific protein on the surface of
HIV-1 virions and as such is the foremost important target to prevent and interfere with
HIV infection. HIV infects the cell through the following sequence of steps: a protein on
the HIV Envelope (Env) spike, gp120, binds to CD4, a receptor on helper T cells, which
then triggers a conformational change of gp120 so that it can bind with the T cell’s
coreceptor. Upon binding to the coreceptor, it draws the envelope spike sufficiently close
to fuse with the T cell’s membrane and pushes the capsid, which contains the genetic
information into the cell and thereby infects the cell. 2 Therefore, a compound that could
bind to Env tightly with specificity, affinity and breadth should be capable to inactivate or
prematurely deactivate Env on the virus and infected cells. In doing so, such compounds
could inhibit HIV infection and possibly eradicate the infected cells.
Recently, the Smith group at Penn has reported several syntheses of small molecule CD4mimetic compounds (CD4mc), including the lead compound, BNM-III-170 as bis-TFA
salt (+)-1, which binds to the viral Env, gp120 and interferes with HIV-1 entry. Employing
structure-based design, along with crystallography and computational analysis, these target
compounds are based on compounds identified by high-throughput screening by Debnath
et al.3 In 2014, the development of the small molecule CD4mc, (+)-DMJ-I-228 and (+)DMJ-II-121 displayed antagonist activity in assays and HIV-1 entry inhibition.4 Then, a
new generation of more potent CD4mc, JP-III-048 and BNM-III-170 demonstrated direct
anti-viral effect and both improve potency and binding affinity.5,6 Specifically, the
promising bioactivity of BNM-III-170 via synergizing with antibodies has led to the
protection of monkeys for up to 6 months from multiple high-dose intrarectal challenges
with a simian-human immunodeficiency virus (SHIV).7 In addition, collaborations have
demonstrated that (+)-1 can also sensitize HIV-infected cells toward Antibody-Dependent
Cellular Cytotoxicity (ADCC), the only way to eradicate the virus in livings cells. 8 While
CD4mc could help eliminate the virus, it could also bind to the viral shedding to prevent T
cells from killing healthy cells. Therefore, small molecule CD4mc is of foremost important
in the path to investigate HIV and a promising cure.

1

The first generation synthesis of the lead small molecule CD4mc, BNM-III-170 as bisTFA salt (+)-1 (Scheme 1) was capable of producing a few hundred milligrams of (+)-1 in
6.2% yield and in 15 steps starting from 5-bromoindanone 2.5 Protection of the
commercially available 2 as the corresponding dioxolane 3, followed by installation of the
(methylamino)-methyl side chain via lithium-halogen exchange, formylation of the
resulting aryllithium species, reductive amination and dioxolane solvolysis afford ketone
4. The β-ketoester 5 was then formed via treatment with sodium bis(trimethylsilyl)amide
then carboxylated with ethyl cyanoformate. Next, the stereogenicity in the β-hydroxyester
(–)-6 was established through a dynamic-kinetic resolution (DKR) under transfer
hydrogenation condition to achieve excellent enantioselectivity (er >99:1).9 Subsequent
LAH reduction, followed by selective protection of the primary alcohol afforded a diol.
Azidation via treatment with diphenylphosphoryl azide (DPPA) and 1,8diazabicyclo[5.4.0]undec-7-ene (DBU)10, followed by reduction of the azide employing a
palladium catalyzed hydrogenation furnished the primary amine (+)-7. A TBTU-mediated
amide coupling with oxalyl acid 8 then installed the oxalamide moiety in intermediate (+)9.11 Following TBS group removal, the primary alcohol (+)-10 was then subjected to a
microwave-assisted Mitsunobu reaction with tri-N-Boc-guanidine 11 to afford the desired
guanidine derivative (+)-12. Finally, global Boc-removal was achieved in the presence of
TFA, and BNM-III-170 (+)-1 was purified through HPLC as the bis-TFA salt.
Scheme 1. The first generation of Synthesis of (+)-1

Given additional interest in the characteristics and bioactivity profile of the small molecule
CD4mc (+)-1, a multigram synthesis was required. However, some steps from the first generation synthesis have certain disadvantages based on their toxicity, high cost, and
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difficulties that limit their practical application, when implemented in a process synthesis
mode. Take the first step as an example, which has proven to be a sluggish acid-catalyzed
ketalization, given to the use of benzene along with the difficulty to achieve full conversion.
In addition, the early overall synthesis required 12 chromatographic separations and a
HPLC purification of (+)-1. Therefore, there was a clear need to develop a robust and
efficient synthesis. The further development of a process synthesis that largely reduced the
number of chromatography of BNM-III-170 is described herein.
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Results and Discussion
The newly developed process synthesis of BNM-III-170 as the TFA salt is illustrated in
Scheme 2.12 The first undesirable step, the ketalization was replaced by a cheaper and
environmentally more friendly Claisen condensation. Since a mild carbon-carbon bond
formation is required in a late stage intermediate, the aryl bromide motif in starting material
2 was retained throughout the first few steps. Toward this end, a Claisen condensation was
conducted between 5-bromoindanone 2 and diethyl carbonate, employing sodium hydride
as the base. In order to slow down the evolution of hydrogen gas, 2 was slowly added into
a suspension of NaH in diethyl carbonate at 0°C before raising the temperature to 70°C,
and the stirring retained for 2 hours to achieve complete conversion. Then, the desired
sodium salt of 13 and the excess sodium hydride were carefully neutralized with dilute
hydrochloric acid (3N) at 0°C. After extraction with ethyl acetate, the resulting β-ketoester
13 was isolated as a mixture of keto and enol tautomers (6:1) and then directly subjected
to the dynamic-kinetic resolution (DKR) under transfer hydrogenation to generate the cis
stereogenicity between hydroxyl group and the ester group of β-hydroxyester 14. A
positive result indicates that a decreased catalyst loading (0.5 mol%) and the amount of
azeotrope (Formic acid: Triethylamine=5:2) did not affect the yield (92%) and
enantioselectivity (er >99:1).
The ester group of 14 was then reduced with LiAlH4, followed by a Fieser & Fieser
workup13, to afford the corresponding diol 15 that was further purified via trituration from
a mixture of ethyl acetate and hexanes (v/v 1:20). It was important to use ether as opposed
to THF as solvent for the Fieser & Fieser workup to furnish a granular precipitate.
Following selective TBS protection of primary alcohol and trituration, bromide 16 was
next converted to aldehyde 17 via lithiation-halogen exchange followed by capturing the
resulting aryl lithium with DMF.
The Boc-protected (methylamino)-methyl side chain of 18 was then installed via a facile
reductive amination, followed by Boc protection of the corresponding secondary amine.
The secondary hydroxyl group in 19 was then converted to an azide 20 with inversion of
stereochemistry. This reaction was conducted with a lower loading of DPPA and DBU (1.2
equiv. versus 3 equiv. in the first generation synthesis) and in a shorter reaction time (4
hours instead of overnight) than the earlier synthesis. The resulting reaction mixture was
then added to water and then extracted with ether. Removal of the solvent gave 20 as a red
oil. Without further purification, a highly efficient homogeneous nickel chloride-catalyzed
reduction led to amine (+)-7. The reduction was completed after 4 hours in the presence of
10 mol% NiCl2•6H2O, compared to the 24 hours with 10 mol% Pd/C employed in the firstgeneration synthesis.
Aminolysis with a more atom-economical reaction, employing ester 21 instead of the
corresponding acid 8 as in the first synthesis, in conjunction with K2CO3 and 3-nitrophenol
afforded (+)-9 at 65°C in 48 hours.14 This result can be explained by the greater
electrophilicity of ester 21 and presumably because of the more reactive intermediate ester
generated in situ by transesterification of 21 with the phenoxide. The excess amount of 33
was then hydrolyzed with aqueous K2CO3 and the resulting potassium salt removed via
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filtration. Next, removal of the TBS group was achieved via addition of a solution of HCl
in 3:1:1 (v/v/v) THF-MeOH-water (pH=1) and stirred overnight. The resulting suspension
was then diluted with aqueous NaHCO3 and the precipitated product filtered as a damp
solid. Taking advantage of the low solubility of (+)-10, purification with an ethereal wash
then furnish (+)-10 as an off white powder.
Scheme 2. New Synthetic Route of BNM-III-170 bis-TFA salt (+)-1
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Alcohol (+)-10 was then converted to mesylate 22 with methane sulfonyl chloride in a 1:4
(v/v) DMF-THF solution, which in turn could be easily purified via filtration as the off
white solid in 92% yield. Next, mesylate 22 was converted to the phthalimide 23 via a
Gabriel amine synthesis to introduce the nitrogen atom.15 Following treatment of the
hydrazine hydrate (5equiv.) in THF-ethanol (v/v 1:1) at 50°C, the primary amine 24 was
obtained. Addition of 5 wt% aqueous Na2CO3 then dissolved the phthalhydrazide
byproduct, while the desired product 24 nicely precipitated as a pale yellow solid.
By employing commercially available di-Boc-pyrazolecarboximidamide, the guanidine
group was next installed successfully by stirring 24 and excess amount of 25 in DMF
overnight. Addition of a sacrificial polyamine, ethylenediamine, followed by extraction
with 5 wt% aqueous NaHSO4 and ethyl acetate as the solvent readily removed the slight
excess of guanidine 25. After removal of the solvent, the penultimate product (+)-12 was
then purified by the first column throughout the synthesis as an off white solid. Last,
dropwise addition of TFA leaded to Boc deprotection, with the TFA salt of (+)-1
precipitating from trituration of a solution of MeOH-ethyl acetate-hexanes (1:4:4) as a
white powder. The overall sequence proceeded in 16 steps and a 9.64% overall yield with
only one column compared to the first-generation synthesis which requires 15 steps in 6.2%
overall yield with 12 column purifications.
After the contribution to the design and develop of the process synthesis, transitioning it
from milligram to decagram scale, 45 grams of BNM-III-170 as TFA salt has been
synthesized for animal studies since joining the Smith group. Studies have shown that
BNM-III-170 not only has direct antiviral effect, but also hold the promise of a better
treatment for HIV than ART (Antiretroviral treatment). Moreover, the process synthesis
will clearly aid the investigation on a mechanism to inhibit HIV-1 entry into cells and
eventually to the eradication of HIV from infected cells in livings and possibly individuals.
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Conclusion
In summary, an effective enantioselective process synthesis of BNM-III-170 as the bisTFA salt (1), employing 16-steps that proceeds in 9.64% overall yield has been achieved
(Scheme 2). The scalable process synthesis versus the first-generation synthesis pleasingly
obviated a tedious end-game HPLC purification, with flash chromatographic separations
avoided in all but one step: that is, a final filtration through a plug of silica.
The stereogenicity of the BNM-III-170 bis-TFA salt (+)-1 was established via a rutheniumcatalyzed transfer hydrogenation by virtue of a DKR, and the aromatic side chain was
installed via alkyllithium-mediated formylation, followed by a reductive amination process.
The oxalamide moiety was then installed by an aminolysis protocol, and the primary amine
necessary for introduction of the guanidine group was attached via a Gabriel amine
synthesis. Pleasingly, the overall process has now been demonstrated on a 20-gram scale
of starting material 2 to prepare the 6.17 grams of BNM-III-170 bis-trifluoroacetate salt
(+)-1 and 45 grams have been synthesized since joining the laboratory.
Future Work
Although the lead CD4mc, BNM-III-170, could inhibit the HIV-1 entry and sensitize the
infected cells to ADCC, there is still possible improvements for the bioactivity. The Smith
group, HIV project team, has been working on structural activity relationship (SAR)
studies based on the high-throughput screening hits NBD-556 and NBD-557 (Figure 1.)
identified by Debnath and coworkers.3 The target has been divided into three regions:
aromatic ring in Region I, the oxalamide linker in Region II, and the substituted piperidine
ring in Region III. Specifically, analysis of the co-crystal structures and the computational
studies show that additional protein ligand interactions with hotspot in the Phe43 cavity,
particularly with the highly conserved Asp 368 residues would greatly enhanced the activity
of the CD4mc. Therefore, new CD4mc analogs should be synthesized to investigate its
deeper potential to cure HIV.

Figure 1. SAR studies from HTS hits and divided regions

More biological studies could be conducted due to the design and development of this
efficient process synthesis, since monkey and mice studies need multigrams of compound
to proceed. Within our collaborative NIH P01 program, ADCC, X-ray crystallography and
computational experiments will list BNM-III-170 as a reference and provide more insights
to new compounds.
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Materials and Methods
General Methods: All reactions were conducted in oven-dried glassware under an inert
atmosphere of nitrogen or argon, unless otherwise stated. All solvents were reagent or high
performance liquid chromatography (HPLC) grade. Anhydrous CH2Cl2, THF, Et2O were
obtained from the Pure SolvTM PS-400 system under a nitrogen atmosphere. All reagents
were purchased from commercially available sources and used as received. Reactions were
magnetically stirred under a nitrogen atmosphere, unless otherwise noted and reactions
were monitored by either thin layer chromatography (TLC) with 0.25 mm E. Merck precoated silica gel plates or analytical liquid chromatography mass spectrometry (LCMS).
Yields refer to chromatographically and spectroscopically pure compounds. When the
compound is carried crude to the next reaction, the crude product is placed under vacuum
pressure until entirely dry from solvent. Optical rotations were measured on a JASCO P2000 polarimeter. Proton (1H) and carbon (13C) NMR spectra were recorded on a Bruker
Avance III 500 MHz or Avance Neo 400 MHz at 305 K. Data reported as following:
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, dd = doublet of doublet, m
= multiplet), coupling constant (Hz), integration. Chemical shifts (δ) are reported in parts
per million (ppm) relative to chloroform (δ 7.26), acetone (δ 2.05), methanol (δ 3.31), or
dimethyl sulfoxide (δ 2.50) for 1H NMR, and chloroform (δ 77.16), acetone (δ 29.84,
206.26), methanol (δ 49.00), or dimethyl sulfoxide (δ 39.52) for 13C NMR. Infrared spectra
were recorded using a JASCO 480-Plus FT-IR spectrometer. High-resolution mass spectra
(HRMS) were recorded at the University of Pennsylvania Mass Spectroscopy Service
Center on either a VG Micromass 70/70H or VG ZAB-E spectrometer. Preparative scale
HPLC was performed with a Gilson 333/334 preparative pump system equipped with a 5
mL injection loop, Sunfire C18 OBD column (5 µm packing material, 19 x 100 mm column
dimensions) equipped with a UV-Vis dual wavelength (210 and 254 nm) detector and 215
liquid handling module. Solvent systems were comprised of H2O containing 0.1%
trifluoroacetic acid, and acetonitrile containing 0.1% trifluoroacetic acid. SFC purifications
and analyses were performed with a JASCO system equipped with a Chiralpak IA column
(10 mm x 250 mm), a PU-280-CO2 plus CO2 Delivery System, a CO-2060 plus Intelligent
Column Thermostat, an HC-2068-01 Heater Controller, a BP-2080 plus Automatic Back
Pressure Regulator, an MD-2018 plus Photodiode Array Detector (200 - 648 nm), and PU2080 plus Intelligent HPLC Pumps. Lyophilization was performed in a Labconco FreeZone
12 Plus lyophilizer (0.28 mbar). The purity of BNM-III-170 was judged by NMR and
HPLC (>95%).
General procedure for process scale synthesis of BNM-III-170 (+)-1

Ethyl 5-Bromo-1-oxo-2,3-dihydro-1H-indene-2-carboxylate
13.
To a stirring
suspension of sodium hydride (7.58 g, 60 % dispersion in oil, 189.5 mmol, 2 equiv.) in
THF (200 mL) at 0 ºC was charged with diethyl carbonate (34.4 mL, 284.3 mmol, 3 equiv.).
Neat 5-bromo-indanone (20 g, 94.7 mmol) was added to this suspension in ten portions.
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(caution: significant H2 (g) evolution will occur; maintain a strong flow of argon with
continuous venting.) The resulting mixture was continued to stir at 0 ºC until gas evolution
subsided (40 minutes on this scale). The resulting brown mixture was then slowly brought
up to 70 ºC whereupon the reaction mixture turned into a dark cake a few minutes after
reflux began. This mixture was aged at 70 ºC for 2 hours. The reaction mixture was then
allowed to cool to room temperature and then diluted with EtOAc (150 mL). The resulting
mixture was further cooled at 0 ºC, to which aqueous HCl (3 N, 100 mL) was added
dropwise, and the solids broke down and dissolved. The organic layer was separated. The
aqueous layer was extracted with EtOAc (2 x 100 mL). The organic layers were combined,
dried over Na2SO4, and filtered through Celite. The Celite pad was further washed with
EtOAc (200 mL). The filtrate was concentrated in vacuo to give the brown solid that
comprised of a mixture of the keto and enol tautomers (6/1, crude). This material was
directly used for the next step without further purification. 1H NMR (500 MHz, CDCl3,
mixture of tautomers, keto/enol=1/2) d 10.39 (s, 0.66H), 7.69 (s, 0.33H), 7.66 – 7.57 (m,
0.96H), 7.57 – 7.43 (m, 1.60H), 4.32 (q, J = 7.1 Hz, 1.34H), 4.25 (q, J = 7.1 Hz, 0.66H),
3.71 (dd, J = 8.3, 4.0 Hz, 0.33H), 3.62 – 3.42 (m, 1.65H), 3.35 (dd, J = 17.5, 8.3 Hz, 0.33H),
1.37 (t, J = 7.1 Hz, 1.98H), 1.31 (t, J = 7.1 Hz, 0.97H); 13C NMR (125 MHz, CDCl3,
mixture of tautomers, keto/enol=2/1) d 198.33, 168.78, 155.26, 145.06, 136.09, 134.31,
131.66, 131.03, 130.31, 130.01, 128.22, 125.95, 123.94, 122.05, 102.92, 62.04, 60.41,
53.44, 32.60, 30.09, 14.59, 14.33; IR (thin film, KBr) 2980, 2359, 1715, 1655, 1420, 1180,
1100 1056 cm-1; HRMS (ESI) calculated for C14H14BrNO3Na [M+CH3CN+Na]+ 346.0055,
found 346.0069.

Ethyl (1S,2S)-5-bromo-1-hydroxy-2,3-dihydro-1H-indene-2-carboxylate (-)-14. To a
solution of β-ketoester 13 (26.8 g, 94.7 mmol) in CH2Cl2 (28 mL) at ambient temperature
was added 5:2 formic acid/triethylamine solution (20 mL), followed by the addition of
RuCl(p-cymene)[(S,S)-Ts-DPEN] (301 mg, 0.47 mmol, 0.5 mol%) in one portion. The
reaction mixture was stirred at room temperature for 64 hours, at which point CO2 gas
evolution had ceased and crude NMR indicated complete consumption of 13. The reaction
was diluted with CH2Cl2 (50 mL) and then treated with H2O (100 mL). The aqueous layer
was extracted with CH2Cl2 (2 x 50 mL). The organic layers were combined, dried over
Na2SO4, filtered, and concentrated in vacuo to give the product as a brown solid, which
was used directly for the next step without further purification. 1H NMR (500 MHz, CDCl3)
d 7.44 – 7.35 (m, 2H), 7.29 (d, J = 8.0 Hz, 1H), 5.32 – 5.22 (m, 1H), 4.23 (q, J = 7.1 Hz,
2H), 3.45 - 3.32 (m, 2H), 3.15 – 3.03 (m, 1H), 1.31 (t, J = 7.1 Hz, 3H); 13C NMR (125
MHz, CDCl3) d 172.68, 144.19, 141.78, 130.35, 128.06, 126.54, 122.98, 75.23, 61.09,
49.59, 32.71, 14.27; IR (thin film, KBr) 3448, 2980, 1735, 1598, 1472, 1442, 1408, 1374
cm-1; HRMS (EI) calculated for C12H13BrO3 [M]+ 284.0048, found 284.0052; Optical
rotation crude [a]D22 –5.8 (c = 0.76, CH2Cl2), purified [a]D22 –7.7 (c = 2.04, CH2Cl2).
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(a)

(b)

10

(c)

Figure 2. Chiral SFC (Supercritical Fluid Chromatography) results to determine the
Enantiomeric ratio (er) of (-)-14. SFC conditions: column: Chiralpak IA; eluent: 10%
MeOH in supercritical CO2; flow rate: 4 mL/min; pressure: 12 MPa; Retention times: (–)14: 4.5 min., (+)-14: 6.0 min. (a) Racemic material was prepared by mixing (-)-14 and (+)14. (b) (-)-14 was synthesized by using 0.5 mol% RuCl(p-cymene)[(S,S)-Ts-DPEN] as a
catalyst. (c) (+)-14 was synthesized by using 0.5 mol% RuCl(p-cymene)[(R,R)-Ts-DPEN]
as a catalyst.

(1S,2R)-5-Bromo-2-(hydroxymethyl)-2,3-dihydro-1H-inden-1-ol (-)-15. To a solution
of 16 (27.0 g, 94.7 mmol) in dry Et2O (470 mL) at 0 ºC was added lithium aluminum
hydride pellets (4.3 g, 113.6 mmol, 1.2 equiv.) in one portion. The reaction mixture was
further stirred vigorously at 0 ºC for 4 hours. To the resulting gray mixture, 4.3 mL of water
was slowly added, followed by slow addition of 4.3 mL of 15% aqueous NaOH. Additional
12.9 mL of water was added and the reaction mixture was allowed to warm up to room
temperature and stirred for 30 minutes. The resulting precipitate was removed via vacuum
filtration, and this solid was washed with Et 2O (700 mL). The filtrate was then filtered
through Celite, and the Celite pad was further rinsed with Et 2O (300 mL). The filtrate was
concentrated in vacuo. The resulting residue was dispersed in EtOAc (20 mL) followed by
dilution with Hexanes (400 mL). The resultant brown solid (18.18 g, 79% yield over 3
steps) was collected by Büchner funnel and rinsed with hexanes to give the product as a
brown powder. This material was used directly for the next step without further purification.
1
H NMR (500 MHz, CDCl3) d 7.43 – 7.33 (m, 2H), 7.26 (d, J = 7.5 Hz, 1H), 5.26 (d, J =
6.5 Hz, 1H), 3.99 – 3.81 (m, 2H), 2.98 - 2.81 (m, 2H), 2.76 – 2.65 (m, 1H), 2.51 (brs, 1H);
13
C NMR (125 MHz, CDCl3) d 145.39, 143.19, 130.22, 128.37, 126.33, 122.86, 62.90,
45.31, 32.75; IR (thin film, KBr) 3397, 2957, 2939, 2884, 2359, 2083, 1652 cm -1; HRMS
(EI) calculated for C10H11BrO2 [M]+ 241.9942, found 241.9930; Optical rotation crude
[a]D22 –16.6 (c = 1.39, CH2Cl2), purified [a]D22 –7.6 (c = 1.14, CH2Cl2).
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(1S,2R)-5-Bromo-2-(((tert-butyldimethyls-lyl)oxy)methyl)-2,3-dihydro-1H-inden-1-ol
(-)-16. To a suspension of diol 15 (18.18 g, 74.8 mmol) in CH2Cl2 (150 mL) at 0 ºC was
added imidazole (10.18 g, 149.6 mmol, 2.0 equiv.) in one portion and stirred for 10 minutes.
To this mixture was added a solution of tert-butyldimethylsilyl chloride (11.27 g, 74.8
mmol, 1.0 equiv.) in CH2Cl2 (50 mL) dropwise over 30 minutes. The reaction mixture was
stirred at 0 ºC for 30 minutes. The resulting mixture was treated with H2O (100 mL). The
aqueous phase was then extracted with CH2Cl2 (2 x 50 mL), the organic layers were dried
over Na2SO4, filtered, and concentrated in vacuo. The impurities were precipitated by using
Et2O/hexanes mixture (diluted with 30 mL of Et2O followed by addition of 200 mL of
Hexanes). The resulting precipitate was filtered through Celite, and the Celite pad was
further rinsed with Hexanes (100 mL). The filtrate was concentrated in vacuo to give the
product as a brown oil, which was used directly for the next step without further
purification. 1H NMR (500 MHz, CDCl3) d 7.38 – 7.32 (m, 2H), 7.29 (d, J = 8.5 Hz, 1H),
5.21 (d, J = 6.6 Hz, 1H), 3.96 (dd, J = 10.3, 4.6 Hz, 1H), 3.86 (dd, J = 10.3, 7.1 Hz, 1H),
2.91 (dd, J = 16.1, 8.2 Hz, 1H), 2.81 (dd, J = 16.1, 6.4 Hz, 1H), 2.74 – 2.62 (m, 1H) 0.85
(s, 9H), 0.08 (s, 3H), 0.05 (s, 3H); 13C NMR (125 MHz, CDCl3) d 144.84, 143.96, 130.03,
127.96, 126.41, 122.26, 76.83, 63.66, 44.97, 33.25, 25.85, 18.16, -5.37, -5.48; IR (thin film,
KBr) 3434, 2953, 2928, 2856, 1652, 1599, 1471 cm-1; HRMS (EI) calculated for
C16H23BrOSi [M-H2O]+ 338.0702, found 338.0701; Optical rotation crude [a]D22 –2.4 (c =
1.30, CH2Cl2), purified [a]D22 –4.1 (c = 0.78, CH2Cl2).

(1S,2R)-2-(((tert-Butyldimethylsilyl)oxy)methyl)-1-hydroxy-2,3-dihydro-1H-indene5-carbaldehyde (-)-17. To a solution of secondary alcohol 16 (25.1 g, 70.2 mmol) in dry
THF (200 mL) at –78 ºC, MeLi (3.1 M in diethoxymethane, 27.2 mL, 84.2 mmol, 1.2 equiv.)
was added dropwise for 10 minutes and allowed to stir at the same temperature for 10
minutes. n-BuLi (2.5 M in hexane, 33.7 mL, 84.2 mmol, 1.2 equiv.) was added dropwise
over 10 minutes. The resulting dark solution was stirred at –78 ºC for 10 minutes, to which
dry DMF (27.2 mL, 351 mmol, 5.0 equiv.) was added dropwise for 5 minutes. The reaction
mixture was allowed to stir at room temperature for 1 hours. The resulting solution was
treated with sat. NH4Cl (100 mL) under ice bath, and then the resulting biphasic mixture
stirred vigorously at room temperature for 10 minutes. The volatiles were then evaporated
on a rotary evaporator. The residue was extracted with Et 2O (3 x 50 mL), the organic layers
combined, dried over Na2SO4, filtered, and concentrated in vacuo to give the product as a
brown oil, which was used directly for the next step without further purification. 1H NMR
(500 MHz, CDCl3) d 9.95 (s, 1H), 7.76 – 7.68 (m, 2H), 7.55 (d, J = 7.6 Hz, 1H), 5.29 (t, J
= 6.2 Hz, 1H), 3.95 (dd, J = 10.4, 4.7 Hz, 1H), 3.84 (dd, J = 10.4, 6.8 Hz, 1H), 3.61 (d, J =
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6.0 Hz, 1H), 2.98 (dd, J = 16.2, 8.1 Hz, 1H), 2.86 (dd, 16.2, 5.6 Hz, 1H), 2.79 – 2.65 (m,
1H), 0.80 (s, 9H), 0.06 (s, 3H), 0.01 (s, 3H); 13C NMR (125 MHz, CDCl3) d 192.43, 151.99,
143.31, 136.88, 129.68, 125.65, 125.32, 77.53, 63.84, 44.90, 33.21, 25.86, 18.16, -5.36, 5.46; IR (thin film, KBr) 3445, 2928, 2856, 1694, 1611, 1582, 1471, 1435 cm-1; HRMS
(EI) calculated for C17H24O2Si [M-H2O]+ 288.1546, found 288.1562; Optical rotation crude
[a]D23 -3.2 (c = 0.75, CHCl3), purified [a]D22 -9.2 (c = 1.20, CHCl3).

(1S,2R)-2-(((tert-butyldimethylsilyl)oxy)methyl)-5-((methylaminuteso)methyl)-2,3dihydro-1H-inden-1-ol (+)-18. To a solution of the aldehyde 17 (21.5 g, 70.2 mmol) in
MeOH (70 mL) was added 40 wt% MeNH2 (18.2 mL, 210.6 mmol, 3.0 equiv.) at 0 ºC. The
resulting solution was stirred at 0 ºC for 30 minutes, followed by the addition of NaBH4
(6.64 g, 175.5 mmol, 2.5 equiv.) in portions. The resulting suspension was continued to stir
at 0 ºC for 2 hours. The reaction mixture was then treated with sat. NaHCO3 (50 mL) and
then H2O (50 mL). The resulting mixture was allowed to warm to room temperature and
extracted with CH2Cl2 (3 x 50 mL). The organic layers were combined, dried over Na2SO4,
filtered, and concentrated in vacuo to give the secondary amine as an orange oil, which was
used in the next step without further purification. 1H NMR (500 MHz, CDCl3) d 7.36 (d, J
= 7.7 Hz, 1H), 7.19 (s, 1H), 7.16 (d, J = 7.7 Hz, 1H), 5.21 (d, J = 6.4 Hz, 1H), 3.96 – 3.83
(m, 2H), 3.73 (s, 2H), 3.43 (brs, 2H), 2.87 (dd, J = 16.0, 8.1 Hz, 1H), 2.80 (dd, J = 16.0,
6.8 Hz, 1H), 2.71 – 2.58 (m, 1H), 2.41 (s, 3H), 0.85 (s, 9H), 0.07 (s, 3H), 0.04 (s, 3H); 13C
NMR (125 MHz, CDCl3) d 144.13, 142.96, 138.48, 127.11, 124.87, 124.76, 76.44, 63.42,
55.26, 45.45, 35.04, 33.13, 25.78, 18.07, -5.44, -5.52; IR 2928, 2360, 1471, 1360, 1254,
1079 cm-1; HRMS (EI) calculated for C18H31NO2Si [M]+ 321.2124, found 321.2117;
Optical rotation crude [a]D24 +2.0 (c = 0.58, CHCl3), purified [a]D23 +3.1 (c = 0.53, CHCl3).

tert-Butyl(((1S,2R)-2-(((tert-butyldimethylsilyl)oxy)methyl)-1-hydroxy-2,3-dihydro1H-inden-5-yl)methyl)(methyl)carbamate (+)-19. To a solution of the amine 18 (22.1
g, 68.7 mmol) was dissolved in CH2Cl2 (70 mL) and this solution was cooled at 0 ºC, to
which a solution of Boc2O (13.49 g, 61.8 mmol, 0.9 equiv.) in CH2Cl2 (20 mL) was added
dropwise for 30 minutes. The reaction mixture was stirred for 1 hours at 0 ºC. The solvent
were then evaporated on a rotary evaporator to give crude carbamate 19 as an amber oil,
which was used directly for the next step without further purification. 1H NMR (500 MHz,
CDCl3) d 7.38 (d, J = 7.7 Hz, 1H), 7.08 (brs, 2H), 5.26 (dd, J = 5.7, 5.2 Hz, 1H), 4.4 (s,
2H), 4.01 – 3.94 (m, 1H), 3.92 – 3.85 (m, 1H), 3.24 (s, 1H), 2.94 – 2.86 (m, 1H), 2.85 –
2.72 (m, 4H), 2.71 – 2.63 (m, 1H), 1.48 (s, 9H), 0.85 (s, 9H), 0.08 (s, 3H), 0.05 (s, 3H);
13
C NMR (100 MHz, CDCl3, mixture of rotamers) d 156.15/ 155.86, 143.93, 142.97,
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138.25, 126.45/125.90, 124.81, 124.10/123.45, 79.65, 76.77, 63.62, 52.58/51.92, 45.20,
33.82, 33.25, 28.50, 25.80, 18.09, -5.43, -5.53; IR (thin film, KBr) 3456, 2930, 1808, 1694,
1462, 1392, 1371, 1213, 1120 cm-1; HRMS (ESI) calculated for C23H39NO4SiNa [M+Na]+
444.2546, found 444.2550; Optical rotation crude [a]D22 -1.5 (c = 0.99, CHCl3), purified
[a]D24 +0.2 (c = 1.07, CHCl3).

tert-butyl (((1R,2S)-1-azido-2-(((tert-butyldimethylsilyl)oxy)methyl)-2,3-dihydro-1Hinden-5-yl)methyl)(methyl)carbamate (+)-20. To a solution of the alcohol 19 (29.7 g,
68.7 mmol) in toluene (230 mL) was added diphenylphosphoryl azide (17.7 mL, 82.4 mmol,
1.2 equiv.) dropwise for 10 minutes, followed by dropwise addition of DBU (12.3 mL, 82.4
mmol, 1.20 equiv.) over 30 minutes. During the addition of DBU, the reaction mixture
exhibited mild exotherm. The resulting cloudy mixture was warmed to 70 ºC and continued
to stir at 70 ºC for 4 hours. The resulting red slurry was allowed to cool to room temperature,
and the solvent was evaporated in vacuo. The residue was treated with H2O (200 mL), and
the resulting mixture was extracted with Et 2O (5 x 50 mL). The combined organic layers
were then washed with 10 wt% citric acid (50 mL) and then 10 wt% NaHCO 3 (50 mL),
dried over Na2SO4, filtered, and concentrated in vacuo to give an red oil, which was used
in the next step without further purification. 1H NMR (500 MHz, CDCl3) d 7.31 (d, J = 7.6
Hz, 1H), 7.09 (s, 1H), 4.73 (d, J = 7.6 Hz, 1H), 4.40 (brs, 2H), 3.78 (dd, J = 10.2, 5.4 Hz,
1H), 3.65 (dd, J = 10.2, 6.3 Hz, 1H), 3.06 (dd, J = 16.0, 8.1 Hz, 1H), 2.86 – 2.76 (m, 3H),
2.71 (dd, J = 16.0, 6.5 Hz, 1H), 2.65 – 2.55 (m, 1H), 1.48 (brs, 9H), 0.89 (s, 9H), 0.09 –
0.04 (m, 6H); 13C NMR (125 MHz, CDCl3, mixture of rotamers) d 156.13/155.75, 142.91,
139.49, 138.90, 126.48/126.08, 124.73, 124.33/123.83, 79.67, 67.32, 63.64, 52.56/51.85,
49.45, 33.97, 33.20, 28.48, 25.92, 18.33, -5.35, -5.37; IR (thin film, KBr) 2929, 2857, 2094,
1698, 1472, 1391, 1366, 1252, 1145 cm-1; HRMS (ESI) calculated for C23H38N4O3SiNa
[M+Na]+ 469.2611, found 469.2600. Optical rotation crude [a]D24 +1.5 (c = 0.67, CHCl3),
purified [a]D23 +18.2 (c = 0.83, CHCl3).

tert-Butyl(((1R,2S)-1-amino-2-(((tert-butyldimethylsilyl)oxy)methyl)-2,3-dihydro-1Hinden-5-yl)methyl)(methyl)carbamate 11. To a solution of the azide 20 (30.7 g, 68.7
mmol) was dissolved in MeOH (230 mL). To the resulting solution was added NiCl 2•6H2O
(1.63 g, 6.87 mmol, 0.1 equiv.). After NiCl2•6H2O was completely dissolved, the resulting
solution cooled to 0 ºC and was treated with NaBH4 (7.80 g, 206.1 mmol, 3 equiv.) in
portions such that the reaction mixture maintained mild gas evolution. After the addition
was complete, the reaction mixture was stirred at 0 ºC until the gas evolution had ceased.
The resulting brown solution was then allowed to warm to room temperature and further
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stirred for 4 hours until the reaction mixture became a green suspension. The solvent was
evaporated in vacuo. The residue was diluted with CH2Cl2 (50 mL) and H2O (50 mL), and
then treated with aqueous NH4OH (50 mL, 30 wt%) with stirring. The organic layer was
separated, and the aqueous layer extracted with CH2Cl2 (2 x 50 mL). The organic layers
were combined and filtered through a fritted funnel. The aqueous layer of the filtrate was
removed, the organic layer dried over Na 2SO4, filtered, and concentrated in vacuo to give
crude 7 as an brown oil, which was used in the next step without further purification. 1H
NMR (500 MHz, CDCl3) d 7.35 (d, J = 7.6 Hz, 1H), 7.03 (brs, 2H), 4.37 (brs, 2H), 4.25
(d, J = 7.6 Hz, 1H), 3.97 (brs, 2H), 3.88 – 3.81 (m, 1H), 3.80 – 3.72 (m, 1H), 2.98 (dd, J =
15.9, 8.1 Hz, 1H), 2.82 – 2.73 (m, 3H), 2.65 (dd, J = 15.9, 8.3 Hz, 1H), 2.40 – 2.30 (m,
1H), 1.46 (s, 9H), 0.86 (s, 9H), 0.05 (s, 6H); 13C NMR (100 MHz, CDCl3, mixture of
rotamers) d 156.22/155.95, 143.38/143.12, 142.76, 137.98, 126.31/126.03, 124.11, 123.65,
79.75, 64.69, 59.25, 52.61, 52.23, 33.97, 33.38, 28.57, 26.02, 18.37, -5.24, -5.30; IR (thin
film, KBr) 3387, 2360, 1686, 1391, 1250 cm-1; HRMS (ESI) calculated for C23H41N2O3Si
[M+H]+ 421.2886, found 421.2880; Optical rotation crude [a]D22 -3.3 (c = 0.79, CHCl3),
purified [a]D24 +10.0 (c = 0.78, CHCl3).

tert-butyl(((1R,2S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-1-(2-((4-chloro-3fluorophenyl)amino)-2-oxoacetamido)-2,3-dihydro-1H-inden-5yl)methyl)(methyl)carbamate (+)-9. A mixture of amine 7 (28.9 g, 68.7 mmol), ester 21
(19.2 g, 78.3 mmol, 1.14 equiv.), 3-nitrophenol (1.91 g, 13.74 mmol, 0.2 equiv.), and
K2CO3 (1.90 g, 13.74 mmol, 0.2 equiv.) in THF (100 mL) was stirred at 65 ºC for 48 h.
The resulting suspension was allowed to cool to room temperature and then treated with
10 wt% K2CO3 (50 mL). The resulting mixture was further stirred at room temperature for
6 hours, and then diluted with EtOAc (50 mL). The insoluble material was removed via
vacuum filtration, and the solid was rinsed with EtOAc (2x100 mL). After the filtrates were
combined, the organic layer was separated and washed with 10 wt% K2CO3 (50 mL). The
aqueous layers were combined and extracted with EtOAc (50 mL). The organic layers were
combined and washed with brine, dried over Na 2SO4, filtered, and concentrated in vacuo
to give crude amide 9 as a brown oil, which was used in the next step without further
purification. 1H NMR (400 MHz, CDCl3) d 9.45 (s, 1H), 7.82 – 7.63 (m, 2H), 7.36 (t, J =
8.3 Hz, 1H), 7.31 – 7.23 (m, 1H), 7.16 (d, J = 7.7 Hz, 1H), 7.13 – 7.00 (m, 2H), 5.34 (dd,
J = 8.4, 8.2 Hz, 1H), 4.40 (s, 2H), 3.80 (d, 5.4 Hz, 2H), 3.07 (dd, J = 16.1, 8.3 Hz, 1H),
2.91 – 2.72 (m, 4H), 2.62 – 2.43 (m, 1H), 1.48 (s, 9H), 0.87 (s, 9H), 0.06 (s, 3H), 0.05 (s,
3H); 13C NMR (100 MHz, CDCl3) d 159.37, 158.25 (d, JCF = 248.4 Hz), 157.74,
156.28/155.90, 142.93, 140.65, 138.78, 136.45 (d, JCF = 9.8 Hz), 130.96, 126.64/126.21,
124.27, 123.84, 117.24 (d, JCF = 18.0 Hz), 116.1 (d, JCF = 3.6 Hz), 108.6 (d, JCF = 26.0 Hz),
79.87, 63.95, 57.05, 52.62/51.98, 51.06, 34.07, 33.58, 28.60, 25.96, 18.38, -5.30, -5.31; IR
(thin film, KBr) 3284, 2929, 2857, 1667, 1595, 1516, 1428 cm-1; HRMS (ESI) calculated
for C31H44ClFN3O5Si [M+H]+ 620.2723, found 620.2729; Optical rotation crude [a]D22
+65.8 (c = 2.47, CH2Cl2), purified [a]D24 +60.4 (c = 0.59, CH2Cl2).
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tert-Butyl(((1R,2S)-1-(2-((4-chloro-3-fluorophenyl)amino)-2-oxoacetamido)-2(hydroxymethyl)-2,3-dihydro-1H-inden-5-yl)methyl)(methyl)carbamate
(+)-10.
Crude amide 9 (42.6 g, 68.7 mmol) was dissolved in THF (210 mL), and the resulting
solution was diluted with MeOH (70 mL) and H2O (70 mL), to which conc. HCl (2.5 mL)
was added dropwise. The reaction mixture was stirred at room temperature overnight. The
resulting thick slurry was then treated with sat. NaHCO 3 (50 mL) followed by H2O (200
mL). The insoluble material was collected via vacuum filtration, washed with H 2O (5x50
mL) and then diethyl ether (5 x 50 mL), followed by drying under vacuum to constant
weight to give amide 10 as an off-white powder (13.2 g, 26.2 mmol, 35% yield from diol
17). 1H NMR (400 MHz, DMSO-d6) d 11.06 (s, 1 H), 9.31 (d, J = 8.8 Hz, 1 H), 7.96 (dd,
J = 11.8, 2.0 Hz, 1 H), 7.74 (dd, J = 8.8, 1.2 Hz, 1 H), 7.58 (t, J = 8.7 Hz, 1 H), 7.11 (d, J
= 7.6 Hz, 1 H), 7.07 (s, 1 H), 7.02 (d, J = 7.6 Hz, 1 H), 5.21 (t, J = 7.7 Hz, 1 H), 4.70 (t, J
= 4.8 Hz, 1 H), 4.33 (s, 2 H), 3.61 – 3.45 (m, 2 H), 3.10 – 2.96 (m, 1 H), 2.78 – 2.65 (m, 5
H), 1.41 (s, 9 H); 13C NMR (100 MHz, DMSO-d6, mixture of rotamers) d 159.80, 159.04,
156.83 (d, JCF = 244.0 Hz), 155.22/154.77, 142.67, 142.00, 138.35 (d, JCF = 10.0 Hz),
137.61, 130.59, 125.65, 123.87, 123.60, 117.36 (d, JCF = 3.0 Hz), 114.35 (d, JCF = 17.6
Hz), 108.51 (d, JCF = 25.7 Hz), 78.81, 61.86, 55.91, 51.72/51.04, 48.47, 33.71, 33.38, 28.10;
IR (thin film, KBr) 3268, 1699, 1663, 1516, 1140 cm-1; HRMS (ESI) calculated for
C25H29ClFN3O5Na [M+Na]+ 528.1677, found 528.1684; Optical rotation crude [a]D22
+66.6 (c = 0.42, acetone), purified [a]D24 +65.2 (c = 0.51, acetone).

((1R,2S)-5-(((tert-Butoxycarbonyl)(methyl)amino)methyl)-1-(2-((4-chloro-3fluorophenyl)amino)-2-oxoacetamido)-2,3-dihydro-1H-inden-2-yl)methyl
methanesulfonate (+)-22. Primary alcohol 10 (13.2 g, 26.2 mmol) was added to DMF
(25 mL). The resulting mixture was stirred at room temperature until most of the solid was
dissolved. The resulting suspension was diluted with THF (100 mL), and the resulting
mixture was cooled to 0 ºC, to which triethylamine (7.3 mL, 52.4 mmol, 2 equiv.) was
added in one portion, followed by dropwise addition of methanesulfonyl chloride (4.1 mL,
52.4 mmol, 2 equiv.). The reaction mixture was further stirred at 0 ºC for 2 hours, and then
allowed to warm to room temperature. The resulting suspension was treated with H2O (250
mL). The resulting precipitate was collected via vacuum filtration. The solid was then
washed with H2O (5 x 50 mL) followed by Et2O (5 x 50 mL), dried under vacuum to
constant weight to give mesylate 22 as an off-white solid (14.1 g, 24.1 mmol, 92%). 1H
NMR (400 MHz, DMSO-d6) d 11.07 (s, 1H), 9.44 (d, J = 8.9 Hz, 1H), 7.97 (dd, J = 11.8,
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2.1 Hz, 1H), 7.76 (dd, J = 8.9, 1.2 Hz, 1H), 7.58 (t, J = 8.7 Hz, 1H), 7.17 – 7.09 (m, 2H),
7.07 (d, J = 7.7 Hz, 1H), 5.30 (dd, J = 8.6, 8.5 Hz, 1H), 4.41 (d, J = 5.6 Hz, 2H), 4.35 (s,
2H), 3.21 (s, 3H), 3.16 – 3.06 (m, 1H), 3.05 – 2.93 (m, 1H), 2.84 – 2.71 (m, 4H), 2.50 (s,
9H); 13C NMR (100 MHz, DMSO-d6, mixture of rotamers) d 159.91, 158.81, 156.83 (d,
JCF = 244.0 Hz), 155.22/154.74, 141.47, 141.12, 138.34 (d, JCF = 10.0 Hz), 137.93, 130.59,
125.93, 123.72, 123.60, 117.36 (d, JCF = 3.1 Hz), 114.37 (d, JCF = 17.6 Hz), 108.50 (d, JCF
= 25.7 Hz), 78.83, 71.01, 55.77, 51.68/51.00, 45.28, 36.58, 33.71, 32.93, 28.09; IR (thin
film, KBr) 3282, 3262, 2905, 1696, 1663, 1591, 1518, 1412, 1359 cm-1; HRMS (ESI)
calculated for C26H31ClFN3O7SNa [M+Na]+ 606.1453, found 606.1476; Optical rotation
crude [a]D22 +52.1 (c = 1.08, acetone), purified [a]D24 +47.3 (c = 1.12, acetone).

tert-Butyl(((1R,2R)-1-(2-((4-chloro-3-fluorophenyl)amino)-2-oxoacetamido)-2-((1,3dioxoisoindolin-2-yl)methyl)-2,3-dihydro-1H-inden-5-yl)methyl)(methyl)carbamate
(+)-23. A mixture of mesylate 22 (14.1 g, 24.1 mmol), potassium phthalimide (6.87 g, 37.1
mmol, 1.54 equiv.), and tetrabutylammonium iodide (0.89 g, 2.41 mmol, 0.1 equiv.) in
DMF (80 mL) was stirred at 35 ºC for 3 days. The reaction mixture was allowed to cool to
room temperature and treated with H2O (300 mL) dropwise with vigorous stirring, and the
resulting precipitate collected via vacuum filtration. The solid was washed with H 2O (5 x
50 mL) and then Et2O (5 x 50 mL). The ethereal phase of the filtrate was separated, dried
over Na2SO4, filtered, and concentrated in vacuo. The residue was treated with Et 2O (20
mL), and the insoluble material was collected via vacuum filtration. The combined solids
were dried under vacuum to constant weight to give the phthalimide 23 as a pale yellow
powder (15.0 g, 23.62 mmol, 98%). 1H NMR (400 MHz, DMSO-d6) d 10.89 (s, 1H), 9.38
(d, 8.5 Hz, 1H), 7.90 – 7.78 (m, 3H), 7.77 – 7.70 (m, 2H), 7.65 (d, J = 8.8 Hz, 1H), 7.55 (t,
J = 8.5 Hz, 1H), 7.13 – 6.98 (m, 3H), 5.18 (dd, J = 7.6, 7.5 Hz, 1H), 4.32 (s, 2H), 3.90 –
3.72 (m, 2H), 3.18 – 2.94 (m, 2H), 2.80 – 2.63 (m, 4H), 1.40 (s, 9H); 13C NMR (100 MHz,
DMSO-d6, mixture of rotamers) d 167.91, 159.49, 158.55, 156.75 (d, JCF = 244.1 Hz),
155.17/154.71, 141.79, 141.30, 138.23 (d, JCF = 10.1 Hz), 137.77, 134.20, 131.54, 130.47,
125.78, 123.77, 123.43, 123.00, 117.31, 114.25 (d, JCF = 17.6 Hz), 108.41 (d, JCF = 25.9
Hz), 78.78, 57.74, 51.67/50.98, 44.87, 34.38, 33.67, 28.07; IR (thin film, KBr) 3266, 2975,
2383, 2348, 1769, 1707, 1661, 1594, 1517 cm-1; HRMS (ESI) calculated for
C33H32ClFN4O6Na [M+Na]+ 657.1892, found 657.1864; Optical rotation crude [a]D22
+52.9 (c = 0.50, acetone), purified [a]D24 +54.0 (c = 0.55, acetone).
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tert-Butyl(((1R,2R)-2-(aminomethyl)-1-(2-((4-chloro-3-fluorophenyl)amino)-2oxoacetamido)-2,3-dihydro-1H-inden-5-yl)methyl)(methyl)carbamate
(+)-24.
Phthalimide 23 (15.0 g, 23.62 mmol) was added to THF (180 mL), and the resulting
mixture was warmed to 50 ºC. The resultant solution was charged with EtOH (180 mL).
The resulting suspension was stirred at 50 ºC until a homogeneous solution had formed, to
which hydrazine monohydrate (5.73 mL, 118.1 mmol, 5.0 equiv.) was added dropwise, and
the reaction mixture was continued to stir at 50 ºC for 24 hours. The resulting thick slurry
was allowed to cool to room temperature and then concentrated in vacuo, and the residue
was treated with 5 wt% Na2CO3 (200 mL). The insoluble material was collected via
vacuum filtration, washed with 5 wt% NaHCO3 (100 mL), H2O (100 mL), and then Et2O
(5 x 50 mL). The resulting damp solid was allowed to dry in air followed by drying under
vacuum to constant weight to give amine 24 as a pale yellow solid (9.42 g, 18.66 mmol,
79%). 1H NMR (400 MHz, MeOH-d4) d 7.86 (dd, J = 11.4, 2.3 Hz, 1H), 7.56 – 7.49 (m,
1H), 7.45 (t, J = 8.4 Hz, 1H), 7.24 (d, J = 8.1 Hz, 1H), 7.19 – 7.10 (m, 2H), 5.27 (d, J = 7.5
Hz, 1H), 4.43 (s, 2H), 3.36 – 3.31 (m, 1H), 3.29 – 3.16 (m, 2H), 2.86 -2.65 (m, 5H), 1.48
(s, 9H); 13C NMR (100 MHz, MeOH-d4, mixture of rotamers) d 162.16, 159.49, 159.14 (d,
JCF = 245.7 Hz), 157.54, 142.81, 140.96, 140.05, 139.04 (d, JCF = 9.8 Hz), 131.73,
127.83/127.69, 125.30, 124.96/124.77, 118.09 (d, JCF = 3.6 Hz), 117.26 (d, JCF = 17.9 Hz),
109.76 (d, JCF = 26.3 Hz), 81.33, 59.28, 53.36/52.64, 47.90, 43.39, 35.69, 34.41, 28.70; IR
(thin film, KBr) 3279, 2902, 2386, 1703, 1662, 1595, 1514, 1429 cm-1; HRMS (ESI)
calculated for C25H31ClFN4O4 [M+H]+ 505.2018, found 505.2017; Optical rotation crude
[a]D23 +26.7 (c = 0.85, CH3OH), purified [a]D23 +11.9 (c = 0.85, CH3OH).

The tri-Boc-BNM-III-170 (+)-12. To a slurry of amine 24 (9.42 g, 18.66 mmol) in DMF
(40 mL) was added N,N’-Di-Boc-1H-pyrazole-1-caboxamidine 25 (6.37 g, 20.53 mmol,
1.1 equiv.) in one portion. The reaction mixture was stirred at room temperature for 24
hours, and the resulting solution then treated with ethylenediamine (3 mL). The resulting
mixture was further stirred at room temperature overnight, and then was diluted with ethyl
acetate (100 mL). The resulting solution was treated with 5 wt% NaHSO 4 (200 mL). The
organic layer was separated. The aqueous filtrate was extracted with EtOAc (3 x 50 mL).
The organic layers were combined, washed with H2O (200 mL) and then brine (100 mL),
dried over Na2SO4, filtered, and concentrated in vacuo. The residue was dissolved in
minimal volume of CH2Cl2 (20 mL), and resulting solution was passed through a plug of
silica gel (Hexanes/EtOAc 10/1 to 1/1) to give 12 as a pale yellow solid (7.67 g, 10.26
mmol, 55% yield). 1H NMR (400 MHz, CDCl3) d 11.47 (s, 1H), 9.44 (s, 1H), 8.65 – 8.44
(m, 1H), 7.83 (d, J = 9.3 Hz, 1H), 7.74 (dd, J = 10.5, 1.3 Hz, 1H), 7.36 (t, J = 8.3 Hz, 1H),
7.28 – 7.23 (m, 1H), 7.14 – 7.03 (m, 3H), 5.28 (t, J = 8.6 Hz, 1H), 4.38 (s, 2H), 3.87 – 3.74
(m, 1H), 3.73 – 3.61 (m, 1H), 3.16 (dd, J = 15.3, 7.5 Hz, 1H), 2.87 – 2.58 (m, 5H), 1.56 –
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1.33 (m, 27H); 13C NMR (100 MHz, CDCl3, mixture of rotamers) d 163.57, 159.82, 158.16
(d, JCF = 248.3 Hz), 157.48, 156.39, 156.24/155.86, 153.31, 141.78, 140.24, 138.97, 136.55
(d, JCF = 9.8 Hz), 130.87, 126.84/126.37, 124.29, 123.79, 117.07 (d, JCF = 17.8 Hz), 116.00
(d, JCF = 3.5 Hz), 108.43 (d, JCF = 26.1 Hz), 83.25, 79.86, 79.50, 58.77, 52.53/51.89, 47.99,
43.69, 34.71, 34.04, 28.56, 28.38, 28.02; IR (thin film, KBr) 3285, 2979, 2927, 1722, 1668,
1642, 1515, 1413, 1137 cm-1; HRMS (ESI) calculated for C36H49ClFN6O8 [M+H]+
747.3284, found 747.3290; Optical rotation crude [a]D24 +30.7 (c = 1.32, CHCl3), purified
[a]D24 +33.0 (c = 1.29, CHCl3).

1-((1R,2R)-2-(((amino(iminio)methyl)amino)methyl)-1-(2-((4-chloro-3fluorophenyl)amino)-2-oxoacetamido)-2,3-dihydro-1H-inden-5-yl)-Nmethylmethanaminium 2,2,2-trifluoroacetate 1. To a solution of 12 (7.67 g, 10.26
mmol) in CH2Cl2 (102 mL) at 0 ºC was added a solution of trifluoroacetic acid (31.4 mL,
410.4 mmol, 40 equiv.) in CH2Cl2 (30 mL) dropwise over 30 minutes. The reaction mixture
was allowed to warm to room temperature and then further stirred at room temperature for
14 hours, by which point LC-MS indicated full deprotection. The solvent and excess acid
were then removed in vacuo. The residue was dissolved in methanol (50 mL) and then
diluted with EtOAc (200 mL). The resulting solution was treated hexanes (200 mL), and
the resulting precipitate collected via vacuum filtration. The solid was washed with
Hexanes/EtOAc (1:1 v/v, 300 mL) and was further dried under vacuum to constant weight
to give the bistrifluoroacetate salt 1 as a white powder (6.17 g, 9.14 mmol, 89% yield). 1H
NMR (500 MHz, DMSO-d6) d 11.07 (s, 1 H), 9.47 (d, J = 8.9 Hz, 1 H), 8.81 (s, 2 H), 7.98
(dd, J = 11.8 Hz, 2.2 Hz, 1 H), 7.82 – 7.69 (m, 2 H), 7.60 (t, J = 8.7 Hz, 1 H), 7.35 (s, 1 H),
7.30 (d, J = 7.8 Hz, 1 H), 7.21 (d, J = 7.8 Hz, 1H), 5.18 (t, J = 8.7 Hz, 1 H), 4.10 (s, 2 H),
3.47 – 3.34 (m, 2 H), 3.13 (dd, J = 15.7, 8.0 Hz, 1 H), 2.93 – 2.78 (m, 1 H), 2.68 (dd, J =
15.5, 9.2 Hz, 1H), 2.55 (s, 3 H); 13C NMR (125 MHz, DMSO-d6) d 160.25, 159.53 (q, JCF
= 32.2 Hz, TFA), 158.96, 157.46, 157.01 (d, JCF = 244.1 Hz), 143.54, 141.97, 138.48 (d,
JCF = 9.9 Hz), 131.70, 130.71, 128.58, 126.32, 124.01, 117.50 (d, JCF = 2.7 Hz), 117.13 (q,
JCF = 297.7 Hz, TFA), 114.57 (d, JCF = 17.8 Hz), 108.66 (d, JCF = 25.7 Hz), 57.14, 51.37,
45.56, 43.13, 34.02, 32.11; IR (thin film, KBr) 3277, 2359, 1664, 1521, 1205, 1145 cm-1;
HRMS (ESI) calculated for C21H25ClFN6O2 [M+H]+ 447.1712, found 447.1707. Optical
rotation [a]D24 +37.3 (c = 1.00, CH3OH).
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